Motus GI Holdings, Inc. (MOTS)
| Market Cap | 416.87K |
| Revenue (ttm) | 319,000 |
| Net Income (ttm) | -12.89M |
| Shares Out | 5.21M |
| EPS (ttm) | -28.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 79,947 |
| Open | 0.1000 |
| Previous Close | 0.0770 |
| Day's Range | 0.0730 - 0.1000 |
| 52-Week Range | 0.0520 - 23.4000 |
| Beta | 1.29 |
| Analysts | Strong Buy |
| Price Target | 37.50 (+46,775.0%) |
| Earnings Date | May 8, 2024 |
About MOTS
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida. [Read more]
Financial Performance
In 2023, MOTS's revenue was $319,000, a decrease of -46.11% compared to the previous year's $592,000. Losses were -$12.87 million, -28.88% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for MOTS stock is "Strong Buy" and the 12-month stock price forecast is $37.5.
News
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
FORT LAUDERDALE, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes a...
EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer
PORTLAND, Ore.--(BUSINESS WIRE)--EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Execu...
Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes and ...
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences,...
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders
FORT LAUDERDALE, Fla., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the Company”) (NASDAQ: MOTS), today announced that its special meeting of stockholders held on February 16, 2024 (the...
Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation
FORT LAUDERDALE, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes a...
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering
FORT LAUDERDALE, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes a...
Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update
FORT LAUDERDALE, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes an...
Motus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon
– A special 510(k), according to FDA guidance, is usually reviewed within 30 days of receipt – – Pure-Vu Gen 4 platform opens up the Upper GI market, reduces the cost-of-goods by approximately 50% and...
Motus GI Amends Royalty Agreement
– Amended agreement eliminates approximately $1.0M in contingent royalty obligations from balance sheet – – Canceled royalty rights in exchange for common stock expected to improve Company's stockhol...
Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors
-- David Hochman and Darren Sherman resign from Motus Board of Directors to focus on their executive obligations -- -- David Hochman and Darren Sherman resign from Motus Board of Directors to focus on...
Motus GI to Present at the H.C. Wainwright 25th Annual Global Investment Conference
FORT LAUDERDALE, Fla., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes an...
Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update
FORT LAUDERDALE, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes an...
Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System
FORT LAUDERDALE, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes an...
Motus GI Announces Purchase Agreement for the Pure-Vu System® from Banner Desert Medical Center
FORT LAUDERDALE, Fla., July 20, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes an...
Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 at the Pentax Learning Center
FORT LAUDERDALE, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes an...
Motus GI Announces Appointment of Ravit Ram as Chief Financial Officer
FORT LAUDERDALE, Fla., June 05, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and...
Motus GI Announces $3.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FORT LAUDERDALE, Fla., May 18, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and...
Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission
- Pure-Vu Gastro achieves high usability scores in supporting upper endoscopy procedures with first time users - - On track to submit a 510(k) to the U.S. FDA for the Pure-Vu Gen 4 Gastro device in Q4...
Motus GI Reports First Quarter 2023 Financial Results and Provides Corporate Update
■ Oral presentation at the Digestive Disease Week 2023 featured positive clinical data showing a reduction of 33% in incomplete bowel prep (IBP)in just six months after implementation of the Pure-Vu® ...
Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones
FORT LAUDERDALE, Fla. , April 13, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes a...
Motus GI Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
FORT LAUDERDALE, Fla., March 31, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve...
Motus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring Plan
FORT LAUDERDALE, Fla., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve ...
Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update
FORT LAUDERDALE, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve...